BridgeMD
New treatment option for Ovarian Cancer
Official title Chemotherapy Supported by Autologous Hematopoietic Stem Cells
ClinicalTrials.gov ID: NCT05401162
What this study is testing
- What it's testing
- The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60, women only
You may be able to join if
- 18-60 years old;
- there are chemotherapy indicators for ovarian cancer;
- ovarian cancer diagnosed by histopathology;
- recurrent and metastatic ovarian cancer;
- the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;
You likely can't join if
- patients with bone marrow disease;
- central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;
- patient has severe cardiac insufficiency;
- previous history of allogeneic stem cell transplantation or organ transplantation;
- patients with active bleeding and autoimmune thrombocytopenic purpura;
- patients with chemotherapy contraindications;
See the full eligibility criteria
- 18-60 years old;
- there are chemotherapy indicators for ovarian cancer;
- ovarian cancer diagnosed by histopathology;
- recurrent and metastatic ovarian cancer;
- the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;
- the expected survival time was more than 3 months;
- pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;
- all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;
- the people voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations;
- bone marrow function is good,ability to perform stem cell mobilisation and collection.
- patients with bone marrow disease;
- central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;
- patient has severe cardiac insufficiency;
- previous history of allogeneic stem cell transplantation or organ transplantation;
- patients with active bleeding and autoimmune thrombocytopenic purpura;
- patients with chemotherapy contraindications;
- positive for human immunodeficiency virus (HIV);
- acute or chronic active hepatitis B or hepatitis C infection.
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, Chongqing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, Chongqing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.